Immune disturbances are a profound feature of chronic lymphocytic leukemia (CLL). From an early stage on, immune defects contribute to infectious complications and autoimmune cytopenias (1) . Moreover, the progressively immunosuppressive environment in CLL influences disease advancement and treatment efficacy (2) . The mechanisms underlying these clinical phenomena encompass both the innate and adaptive immune system. At the crossroad of innate and adaptive immunity, natural killer (NK) cells exhibit diminished cytotoxicity, despite an increase in absolute number (3, 4) . NK cells are now recognized to be part of a larger group of innate lymphocytes, collectively referred to as innate lymphoid cells (ILCs) (5) . ILCs fulfill a key part in the initial immune response, tumorsurveillance and tumorigenesis (6) (7) (8) . Yet, the role of ILCs in CLL has not been clarified. Hence we studied the frequency and functionality of ILCs in CLL patients. Early evidence shows that ILCs can play a role in tumor development, chiefly by producing tumor-promoting cytokines and by supporting an immunosuppressive environment. In acute myeloid leukemia (AML) at diagnosis, ILCs are significantly dysregulated in terms of frequency, subtype composition and function (9, 10) . A hallmark feature of lymphoproliferative disorders is the intensive crosstalk between malignant lymphoid cells and other immune cells. To our knowledge, the role of ILCs in lymphoproliferative disorders and particularly in the disturbed CLL immune system has not been characterized. We studied ILCs in CLL patients to establish their frequency, distribution and functionality. Total ILC counts in the peripheral blood were significantly increased in CLL patients in comparison to age-matched HCs ( Figure 1A) . Moreover, the ILC count correlated with the ALC in CLL patients, suggesting a rise in ILCs with disease progression (r 2 = 0.477, p = 0.023; Figure 1B ). Accordingly, the ILC count correlated inversely with time to first treatment (r 2 = 0,259, p = 0.044; Figure 1C ). The activation status of ILCs, as measured by CD69
expression, was similar in CLL patients and HCs (Supplementary Figure 1B) . The absolute counts of both ILC1s and NKp44 -ILC3s were significantly elevated in comparison to HCs ( Figure 1D ). NKp44 + ILC3s were virtually absent in the peripheral blood of both CLL patients and HCs. Yet, the proportion of each ILC subgroup in CLL patients resembled their respective fractions in the HCs ( Figure 1E ). ILC counts did not differ between M-CLL and U-CLL patients ( Figure 1F ). Similarly, ILC subtype distribution of M-CLL patients was equivalent to that of U-CLL (Supplementary Figure 1C) .
Subsequently, we analyzed and compared cytokine production as a marker for ILC functionality. PBMCs from 6 CLL patients and 6 age-matched HCs, with comparable ILC subgroup distribution, were depleted from T and B cells using anti-CD3 and anti-CD19 magnetic microbeads (Miltenyi Biotec). Cells were stimulated with PMA (10 ng/mL; SigmaAldrich) and ionomycin (0,5 µg/mL; Sigma-Aldrich) for 4 hours in the presence of Brefeldin A (10 µg/mL; Invitrogen) and stained extracellularly to identify ILCs (Supplementary Figure 1D) .
Subsequently, cells were stained intracellularly for production of IFN-γ, TNF-α (group 1 ILCs), IL-13 (group 2 ILCs) and IL-22 (group 3 ILCs).
HC derived ILC1 cells produced robust levels of TNF-α. In contrast, TNF-α production in CLL (100 U/mL) for 2 weeks and resorted afterwards, after which the purity for each sample was ≥ 95%. ILC1s were stimulated with IL-12, IL-18 (50 ng/ml, R&D Systems) and PMA/ionomycin as described above and subsequently stained for TNF-α and IFN-γ. NKp44 -ILC3s were stimulated with IL-1β, IL-23 (50 ng/ml, R&D Systems) and PMA/ionomycin and subsequently stained for IL-17A and IL-22.
Again, ILC1s from CLL patients appeared to be functionally impaired when compared to
HCs. In parallel with direct cytokine measurements in the total ILC pool, cultured ILC1s from CLL patients produced less TNF-α ( Figure 2B ). IFN-γ production by cultured ILC1s was unaffected. In contrast with ILC1s, production of IL-17A and IL-22 ( Figure 2C ) of NKp44 -ILC3s was not affected upon culture.
Subsequently, we investigated whether ILC cytokine production was affected by CLL cells. 
PBMCs from HCs (n=3) were depleted from monocytes, T and B cells using anti-CD4, anti-CD8, anti-CD14 and anti-CD19 magnetic microbeads (Miltenyi Biotec
)
